These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 16720462)
21. Neurological manifestations of Fabry disease in female carriers. Bird TD; Lagunoff D Ann Neurol; 1978 Dec; 4(6):537-40. PubMed ID: 217299 [TBL] [Abstract][Full Text] [Related]
22. [alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)]. Okumiya T; Takata T; Sasaki M; Sakuraba H Rinsho Byori; 1997 Feb; 45(2):127-35. PubMed ID: 9120996 [TBL] [Abstract][Full Text] [Related]
23. [Biochemical study of unusual cases of Fabry disease]. Beĭer EM; Karpova EA; Udalova OV; Tsvetkova IV Vopr Med Khim; 1998; 44(5):494-500. PubMed ID: 9916266 [TBL] [Abstract][Full Text] [Related]
24. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. Vedder AC; Cox-Brinkman J; Hollak CE; Linthorst GE; Groener JE; Helmond MT; Scheij S; Aerts JM Mol Genet Metab; 2006 Nov; 89(3):239-44. PubMed ID: 16765076 [TBL] [Abstract][Full Text] [Related]
25. Female Fabry disease patients and X-chromosome inactivation. Juchniewicz P; Kloska A; Tylki-Szymańska A; Jakóbkiewicz-Banecka J; Węgrzyn G; Moskot M; Gabig-Cimińska M; Piotrowska E Gene; 2018 Jan; 641():259-264. PubMed ID: 29079200 [TBL] [Abstract][Full Text] [Related]
26. A successful approach for the detection of Fabry patients in Argentina. Rozenfeld PA; Tarabuso A; Ebner R; Ramallo G; Fossati CA Clin Genet; 2006 Apr; 69(4):344-8. PubMed ID: 16630168 [TBL] [Abstract][Full Text] [Related]
27. Symptoms in carriers of adrenoleukodystrophy relate to skewed X inactivation. Maier EM; Kammerer S; Muntau AC; Wichers M; Braun A; Roscher AA Ann Neurol; 2002 Nov; 52(5):683-8. PubMed ID: 12402273 [TBL] [Abstract][Full Text] [Related]
28. A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted. Miyamura N; Araki E; Matsuda K; Yoshimura R; Furukawa N; Tsuruzoe K; Shirotani T; Kishikawa H; Yamaguchi K; Shichiri M J Clin Invest; 1996 Oct; 98(8):1809-17. PubMed ID: 8878432 [TBL] [Abstract][Full Text] [Related]
29. Japanese patients with Fabry disease predominantly showing cardiac and neurological manifestation with novel missense mutation: R220P. Fukutomi M; Tanaka N; Uchinoumi H; Kanemoto M; Nakao F; Yamada J; Kamei T; Takenaka T; Fujii T J Cardiol; 2013 Jul; 62(1):63-9. PubMed ID: 23608164 [TBL] [Abstract][Full Text] [Related]
30. X-Inactivation patterns in females harboring mtDNA mutations that cause Leber hereditary optic neuropathy. Hudson G; Carelli V; Horvath R; Zeviani M; Smeets HJ; Chinnery PF Mol Vis; 2007 Dec; 13():2339-43. PubMed ID: 18199976 [TBL] [Abstract][Full Text] [Related]
31. X-chromosomal inactivation patterns in women with Fabry disease. Wagenhäuser L; Rickert V; Sommer C; Wanner C; Nordbeck P; Rost S; Üçeyler N Mol Genet Genomic Med; 2022 Sep; 10(9):e2029. PubMed ID: 35971858 [TBL] [Abstract][Full Text] [Related]
32. [Early acroparesthesia in females: a sign disclosing heterozygote Fabry disease]. Larrégue M; Trincal D; Bressieux JM; Fusade T; Tanzer J; Menguy C Ann Dermatol Venereol; 1991; 118(3):191-7. PubMed ID: 1648327 [TBL] [Abstract][Full Text] [Related]
33. Identification of novel mutations in the α-galactosidase A gene in patients with Fabry disease: pitfalls of mutation analyses in patients with low α-galactosidase A activity. Yoshimitsu M; Higuchi K; Miyata M; Devine S; Mattman A; Sirrs S; Medin JA; Tei C; Takenaka T J Cardiol; 2011 May; 57(3):345-53. PubMed ID: 21333496 [TBL] [Abstract][Full Text] [Related]
34. Increased frequency of extremely skewed X chromosome inactivation in juvenile idiopathic arthritis. Uz E; Mustafa C; Topaloglu R; Bilginer Y; Dursun A; Kasapcopur O; Ozen S; Bakkaloglu A; Ozcelik T Arthritis Rheum; 2009 Nov; 60(11):3410-2. PubMed ID: 19877028 [TBL] [Abstract][Full Text] [Related]
35. Clinical and molecular characterization of an extended family with Fabry disease. Wattanasirichaigoon D; Svasti J; Cairns JR; Tangnararatchakit K; Visudtibhan A; Keeratichamroen S; Ngiwsara L; Khowsathit P; Onkoksoong T; Lekskul A; Mongkolsiri D; Jariengprasert C; Thawil C; Ruencharoen S J Med Assoc Thai; 2006 Sep; 89(9):1528-35. PubMed ID: 17100396 [TBL] [Abstract][Full Text] [Related]
36. X chromosome inactivation patterns in normal and X-linked hereditary nephropathy carrier dogs. Bell RJ; Lees GE; Murphy KE Cytogenet Genome Res; 2008; 122(1):37-40. PubMed ID: 18931484 [TBL] [Abstract][Full Text] [Related]
37. Fabry disease in patients with end-stage renal failure: the potential benefits of screening. Bekri S; Enica A; Ghafari T; Plaza G; Champenois I; Choukroun G; Unwin R; Jaeger P Nephron Clin Pract; 2005; 101(1):c33-8. PubMed ID: 15886492 [TBL] [Abstract][Full Text] [Related]
38. Skewing of X-chromosome inactivation in three generations of carriers with X-linked chronic granulomatous disease within one family. Köker MY; Sanal O; de Boer M; Tezcan I; Metin A; Tan C; Ersoy F; Roos D Eur J Clin Invest; 2006 Apr; 36(4):257-64. PubMed ID: 16620288 [TBL] [Abstract][Full Text] [Related]
39. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Orteu CH; Jansen T; Lidove O; Jaussaud R; Hughes DA; Pintos-Morell G; Ramaswami U; Parini R; Sunder-Plassman G; Beck M; Mehta AB; Br J Dermatol; 2007 Aug; 157(2):331-7. PubMed ID: 17573884 [TBL] [Abstract][Full Text] [Related]
40. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Yasuda M; Shabbeer J; Benson SD; Maire I; Burnett RM; Desnick RJ Hum Mutat; 2003 Dec; 22(6):486-92. PubMed ID: 14635108 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]